openPR Logo
Press release

Retinitis Pigmentosa Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024

09-24-2024 10:42 PM CET | Health & Medicine

Press release from: ABNewswire

Retinitis Pigmentosa Pipeline Insights, Treatment Drugs,

DelveInsight's, "Retinitis Pigmentosa Pipeline Insight 2024" report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Retinitis Pigmentosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our comprehensive Retinitis Pigmentosa Pipeline Report to stay informed about the latest advancements. Download copy now @ Retinitis Pigmentosa Pipeline Outlook [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Retinitis Pigmentosa Pipeline Report

* In September 2024:- Janssen Research & Development LLC- Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene. A clinical trial of AAV5-RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)
* In September 2024:- AAVantgarde Bio Srl- A Phase 1/2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Subjects With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa. The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene. The study will also assess the initial efficacy following AAVB-081 administration.
* DelveInsight's Retinitis Pigmentosa pipeline report depicts a robust space with 45+ active players working to develop 45+ pipeline therapies for Retinitis Pigmentosa treatment.
* The leading Retinitis Pigmentosa Companies such as Biogen, Neurotech, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Nacuity Pharmaceuticals, ReNeuron, ID Pharma, Allegro Ophthalmics, SparingVision, Editas Medicine, OiDE OptoEye , and others.
* Promising Retinitis Pigmentosa Therapies such as EA-2353, BS01, CPK850, hRPC, SPVN06, RST-001 , and others.

Dive into our Retinitis Pigmentosa Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ Retinitis Pigmentosa Treatment Therapies [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Retinitis Pigmentosa Emerging Drugs Profile

* BIIB-112: Biogen

BIIB-112 (formerly called NSR-RPGR) consists of a standard AAV8 vector carrying a codon optimized RPGR gene. BIIB112 is in phase II clinical studies for X-linked retinitis pigmentosa treatment. In September 2018, NSR-RPGR was granted orphan drug designation for the treatment of inherited retinal dystrophies due to defects in the RPGR gene from the U.S. Food and Drug Administration.

* QR 1123 (formerly ISIS RHO 2.5Rx): Ionis Pharmaceuticals

QR 1123 (formerly ISIS RHO 2.5Rx) is an antisense oligonucleotide, designed to specifically target the mutant P23H messenger ribonucleic acid (mRNA) in order to reduce the expression of the P23H protein selectively, while preserving expression of the wild type (WT) rhodopsin (RHO) protein. The therapy is currently in Phase II clinical evaluation for the treatment of Retinitis Pigmentosa. In November 2019, ProQR Therapeutics announced that it received Orphan Drug designation (ODD) from the Food and Drug Administration (FDA) for QR-1123. QR-1123 was in-licensed from Ionis Pharmaceuticals in 2018. QR-1123 has also received Fast Track designation from the FDA.

Download the Retinitis Pigmentosa Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ Retinitis Pigmentosa Clinical Trials Assessment [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Retinitis Pigmentosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical
* Molecule Type

Retinitis Pigmentosa Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type

Dive into our detailed Retinitis Pigmentosa Pipeline Report to discover groundbreaking advancements shaping the future of cancer treatment @ Retinitis Pigmentosa Products, Companies, and Unmet Needs [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Retinitis Pigmentosa Pipeline Report

* Coverage- Global
* Retinitis Pigmentosa Companies- Biogen, Neurotech, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Nacuity Pharmaceuticals, ReNeuron, ID Pharma, Allegro Ophthalmics, SparingVision, Editas Medicine, OiDE OptoEye, and others.
* Retinitis Pigmentosa Therapies- EA-2353, BS01, CPK850, hRPC, SPVN06, RST-001, and others.
* Retinitis Pigmentosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Retinitis Pigmentosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Gain valuable insights into emerging therapies and innovations with our Retinitis Pigmentosa Pipeline Report @ Retinitis Pigmentosa Market Drivers and Barriers, Future Perspectives and Analyst Views [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Retinitis Pigmentosa: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Retinitis Pigmentosa - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Retinitis Pigmentosa Collaboration Deals
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* BIIB-112: Biogen
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* N-acetylcysteine-amide: Nacuity Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* SPVN 06: SparingVision
* Drug profiles in the detailed report.....
* Inactive Products
* Retinitis Pigmentosa Key Companies
* Retinitis Pigmentosa Key Products
* Retinitis Pigmentosa- Unmet Needs
* Retinitis Pigmentosa- Market Drivers and Barriers
* Retinitis Pigmentosa- Future Perspectives and Conclusion
* Retinitis Pigmentosa Analyst Views
* Retinitis Pigmentosa Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=retinitis-pigmentosa-pipeline-insights-treatment-drugs-clinical-trials-and-companies-2024]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Retinitis Pigmentosa Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024 here

News-ID: 3666543 • Views:

More Releases from ABNewswire

Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repair Services to Support St. Louis Park Homeowners
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold. Responding to a Growing Need for Water Damage Restoration Property owners across Minnesota are increasingly seeking
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Injury Attorneys Representation in Port Jefferson Station
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents. Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washing Prevents Long-Term Damage in Millsboro DE
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces. In
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection. Market Overview: Understanding Tampa Bay Remodeling Investment Trends Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.

All 5 Releases


More Releases for Retinitis

Shaping the Retinitis Pigmentosa Market in 2025: Innovative Gene Therapy Develop …
How Big Is the Retinitis Pigmentosa Market Expected to Be, and What Will Its Growth Rate Be? In recent times, a significant expansion has been witnessed in the market size of retinitis pigmentosa. The market is set to rise from $11.32 billion in 2024 to $12.22 billion in 2025, delivering a compound annual growth rate (CAGR) of 8.0%. The proliferation in the preceding period is due to progress in genetic
Shaping the Retinitis Pigmentosa Market in 2025: Innovative Gene Therapy Develop …
How Big Is the Retinitis Pigmentosa Market Expected to Be, and What Will Its Growth Rate Be? In recent times, a significant expansion has been witnessed in the market size of retinitis pigmentosa. The market is set to rise from $11.32 billion in 2024 to $12.22 billion in 2025, delivering a compound annual growth rate (CAGR) of 8.0%. The proliferation in the preceding period is due to progress in genetic
Retinitis Pigmentosa Market Growth and Treatment Advancements
The retinitis pigmentosa (RP) market has garnered considerable attention in recent years due to its profound impact on individuals' lives. As one of the leading causes of hereditary blindness, RP is a genetic eye disorder that progressively leads to vision loss. The market for retinitis pigmentosa treatments was valued at USD 14.02 billion in 2023, and with significant advancements on the horizon, it is expected to reach USD 21.40 billion
Retinitis Pigmentosa Market Research and Market Share Insights
The Business Research Company recently released a comprehensive report on the Global Retinitis Pigmentosa Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. Ready to Dive into Something Exciting? Get Your Free Exclusive Sample
Cytomegalovirus Retinitis Market Forecast 2031: Growth and Opportunities
The "Cytomegalovirus Retinitis Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats, alongside
Retinitis Pigmentosa (Retinitis) Market Analysis and Future Prospects for 2030
The world of the retinitis pigmentosa (retinitis) market is a complex and ever-evolving landscape, shaped by consumer demands and technological advancements. In this report, we delve into the depths of this market to provide a profound and comprehensive analysis, catering to a diverse audience that includes manufacturers, suppliers, distributors, and investors. Our primary goal is to empower industry stakeholders with invaluable insights to make informed decisions in a rapidly changing